| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Abbott Laboratories (ABT) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The overall sentiment for Abbott Laboratories is neutral (overall 0.7, positive 2.5, negative -1.8) on 20251121. The forces of Sentiment towards Fundamentals (2.8), Option Sentiment (1.5), Sector Price Trend (1.2), and Price Level Sentiment (0) will drive up the price. The forces of Stock Price Trend (-0.7), Valuation Sentiment (-0.9), and Market Risk Appetite (-1.9) will drive down the price. The swing to upside will be significant considering the high positive sentiment forces (2.5). The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Action | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 | 0% | 0.1% | 128.21 | 69 | 3.41% | 0.16% | 0.7 | -0.7 | Short | 2.8 | -1.5 |
| 2025-11-20 | 1% | 0.1% | 123.98 | 21 | -1.72% | -0.08% | 0.3 | -0.4 | Long | 2.6 | 5.6 |
| 2025-11-19 | 0% | 0% | 126.15 | 43 | -2.96% | 0.16% | -2 | -0.4 | Range | 1.1 | 6.5 |
| 2025-11-18 | 0% | 0% | 130 | 90 | -0.04% | 0.31% | -1.5 | 0.6 | Short | 0.3 | -1.5 |
| 2025-11-17 | 0% | 0% | 130.05 | 94 | -0.44% | 0.47% | -1.7 | 1.3 | Short | 0.5 | -1.5 |
| 2025-11-16 | 0% | 0% | -0.4 | 1 | Long | 0.1 | -1.5 | ||||
| 2025-11-15 | 0% | 0% | -0.8 | 1 | Long | -0.7 | -1.5 | ||||
| 2025-11-14 | 0% | 0% | 130.62 | 103 | 1.05% | 0.56% | -1.5 | 1.3 | Short | -0.7 | -1.5 |
| 2025-11-13 | 0% | 0% | 129.26 | 90 | 0.35% | 0.32% | -1 | 1 | Short | -1 | -1.5 |
| 2025-11-12 | 0% | 0% | 128.81 | 87 | 1.43% | 0.4% | 0.4 | 1 | Short | -0.1 | -1.5 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. | Range refers to range trade strategy. In an uptrend, the price will likely bullback after huge advance. As an investor, you may want to wait for the pullback to open long position. As a trader, you may consider tactical short. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. As a trader, you may consider tactical long. |
| 1 (8) Abbott To Acquire Exact Sciences For About $23 Billion Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per share. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 2 (5) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |
| 3 (7) Abbott’s $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic division that has lost sales from COVID tests. (https://www.forbes.com/) Thu. Nov 20, 2025 | |
| 4 (8) Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 5 (7) Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 6 (8) Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. (https://www.cnbc.com/) Thu. Nov 20, 2025 | |
| 7 (7) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |